Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511335921> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2511335921 endingPage "e18066" @default.
- W2511335921 startingPage "e18066" @default.
- W2511335921 abstract "e18066 Background: Standard treatment for patients with good PS stage IIIB/IV NSCLC currently includes a two- drug platinum-based chemotherapy regimen, but optimum treatment for elderly patients is less well defined. Thus, this study has been conducted to assess the efficacy and toxicity of biweekly gemcitabine plus docetaxel in elderly patients with NSCLC. Methods: Patients ≥70 years old with cytological or histological confirmation of advanced (stage IIIB/IV) NSCLC, PS≤1, measurable lesion according RECIST criteria, adequate bone marrow, renal, and hepatic function were included. Patients with prior systemic therapy for NSCLC and/or symptomatic brain metastases were not allowed. Patients received biweekly docetaxel 50 mg/m2 iv, gemcitabine 2,000 mg/m2 iv days 1 and 14, during 24 weeks. Toxicity was evaluated according to CTCAE 3.0. Results: Forty-nine patients were included in this interim analysis, 20.4% PS=0 and 79.6% PS=1. Main characteristics of patients are shown in the Table. Median number of lesions was 3. A total of 151 cycles (median=3, range 1-6) were administered. Median relative dose intensity was 90.0% for docetaxel and gemcitabine. Over 49 patients analysed, 8 patients achieved PR (16.3%), 21 SD (42.9%), 10 PD (20.4%) and 10 (20.4%) were not evaluable (4 due to death, 2 due to adverse event, 1 due to toxicity, 3 due to withdrawal/missing). Overall response rate was 16.3% (95%CI:6.0%-26). Median follow-up time was 4.1 months (0.2-18.4). Toxicities are shown in the Table. Conclusions: Docetaxel and gemcitabine administered every 14 days as first line treatment for advanced disease in elderly NSCLC patients seems to be a safe and active regimen. Patients' characteristics Age (yr) Median 76.0 Range 71.1-84.8 Histology (%) Squamous 38.8 Adenocarcinoma 32.7 Sites of metastases (%) Pleura 25.0 Ganglionar 25.0 Lymph nodes 22.9 Adrenal gland 20.8 Liver 16.7 Bones 14.7 Prior treatment (%) Radiotherapy 8.5 Current smokers (%) 26.5 Main comorbidities (%) COPD 58.5 Cardiovascular 39.0 Help for daily living activities (%) 97.6 Toxicities Grade IV (%) Leucopenia 4.1 Grade III nonhematological (%) Asthenia 12.2 Anorexia 4.1 Febrile neutropenia 6.1 Grade III hematological (%) Leucopenia 8.2 Neutropenia 8.2 No significant financial relationships to disclose." @default.
- W2511335921 created "2016-09-16" @default.
- W2511335921 creator A5003872205 @default.
- W2511335921 creator A5009661827 @default.
- W2511335921 creator A5009912667 @default.
- W2511335921 creator A5017031117 @default.
- W2511335921 creator A5021894737 @default.
- W2511335921 creator A5023205767 @default.
- W2511335921 creator A5024026246 @default.
- W2511335921 creator A5036354181 @default.
- W2511335921 creator A5046160103 @default.
- W2511335921 creator A5046690861 @default.
- W2511335921 date "2010-05-20" @default.
- W2511335921 modified "2023-10-18" @default.
- W2511335921 title "Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in elderly non-small cell lung cancer (NSCLC) patients." @default.
- W2511335921 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e18066" @default.
- W2511335921 hasPublicationYear "2010" @default.
- W2511335921 type Work @default.
- W2511335921 sameAs 2511335921 @default.
- W2511335921 citedByCount "0" @default.
- W2511335921 crossrefType "journal-article" @default.
- W2511335921 hasAuthorship W2511335921A5003872205 @default.
- W2511335921 hasAuthorship W2511335921A5009661827 @default.
- W2511335921 hasAuthorship W2511335921A5009912667 @default.
- W2511335921 hasAuthorship W2511335921A5017031117 @default.
- W2511335921 hasAuthorship W2511335921A5021894737 @default.
- W2511335921 hasAuthorship W2511335921A5023205767 @default.
- W2511335921 hasAuthorship W2511335921A5024026246 @default.
- W2511335921 hasAuthorship W2511335921A5036354181 @default.
- W2511335921 hasAuthorship W2511335921A5046160103 @default.
- W2511335921 hasAuthorship W2511335921A5046690861 @default.
- W2511335921 hasConcept C126322002 @default.
- W2511335921 hasConcept C141071460 @default.
- W2511335921 hasConcept C143998085 @default.
- W2511335921 hasConcept C197934379 @default.
- W2511335921 hasConcept C2776256026 @default.
- W2511335921 hasConcept C2776694085 @default.
- W2511335921 hasConcept C2776907518 @default.
- W2511335921 hasConcept C2778822529 @default.
- W2511335921 hasConcept C2780258809 @default.
- W2511335921 hasConcept C2781190966 @default.
- W2511335921 hasConcept C2781413609 @default.
- W2511335921 hasConcept C29730261 @default.
- W2511335921 hasConcept C31760486 @default.
- W2511335921 hasConcept C71924100 @default.
- W2511335921 hasConcept C90924648 @default.
- W2511335921 hasConceptScore W2511335921C126322002 @default.
- W2511335921 hasConceptScore W2511335921C141071460 @default.
- W2511335921 hasConceptScore W2511335921C143998085 @default.
- W2511335921 hasConceptScore W2511335921C197934379 @default.
- W2511335921 hasConceptScore W2511335921C2776256026 @default.
- W2511335921 hasConceptScore W2511335921C2776694085 @default.
- W2511335921 hasConceptScore W2511335921C2776907518 @default.
- W2511335921 hasConceptScore W2511335921C2778822529 @default.
- W2511335921 hasConceptScore W2511335921C2780258809 @default.
- W2511335921 hasConceptScore W2511335921C2781190966 @default.
- W2511335921 hasConceptScore W2511335921C2781413609 @default.
- W2511335921 hasConceptScore W2511335921C29730261 @default.
- W2511335921 hasConceptScore W2511335921C31760486 @default.
- W2511335921 hasConceptScore W2511335921C71924100 @default.
- W2511335921 hasConceptScore W2511335921C90924648 @default.
- W2511335921 hasIssue "15_suppl" @default.
- W2511335921 hasLocation W25113359211 @default.
- W2511335921 hasOpenAccess W2511335921 @default.
- W2511335921 hasPrimaryLocation W25113359211 @default.
- W2511335921 hasRelatedWork W1983722681 @default.
- W2511335921 hasRelatedWork W1990777236 @default.
- W2511335921 hasRelatedWork W2024219304 @default.
- W2511335921 hasRelatedWork W2098516929 @default.
- W2511335921 hasRelatedWork W2126539868 @default.
- W2511335921 hasRelatedWork W2138054646 @default.
- W2511335921 hasRelatedWork W2322460005 @default.
- W2511335921 hasRelatedWork W2590075607 @default.
- W2511335921 hasRelatedWork W3155373832 @default.
- W2511335921 hasRelatedWork W1980133017 @default.
- W2511335921 hasVolume "28" @default.
- W2511335921 isParatext "false" @default.
- W2511335921 isRetracted "false" @default.
- W2511335921 magId "2511335921" @default.
- W2511335921 workType "article" @default.